# Liminatus Pharma, Inc. (LIMNW) — delisting/forced [announced]
Source: sec.gov · situation sit_f3ddb36f8fb1dfc1b4b8 · public 8249150392378550742 · retrieved 2026-08-19T12:50:15.295Z

## Overview
Liminatus Pharma, Inc. is a biotechnology company developing novel immune-modulating cancer therapies, including antibody-based immunotherapies and cellular therapies for solid tumors and hematologic malignancies; its lead candidate is IBA101, a humanized anti-CD47 monoclonal antibody.

Liminatus Pharma, Inc., a biotechnology company developing immune-modulating cancer therapies, executed a 1-for-50 reverse stock split of its common stock, effective August 20, 2026, to regain compliance with Nasdaq listing requirements. The company's Board approved the reverse split on August 3, 2026, following stockholder approval at the annual meeting held the same day. The reverse split reduces the outstanding share count from approximately 67,160,362 shares (as of July 2, 2026) to approximately 1,343,208 shares. On July 31, 2026, the Nasdaq Hearings Panel granted the company's request to transfer from The Nasdaq Global Market to The Nasdaq Capital Market and granted an exception to regain compliance with the minimum bid price rule by September 3, 2026. The company expects the reverse split will enable it to meet the $1.00 minimum closing bid price requirement.

## Key dates
- Announced 2026-08-18 · Vote 2026-08-03 · Expiry 2026-09-03

## Timeline
- 2026-08-18 · 8-K (0001104659-26-098335): 8-K - Liminatus Pharma, Inc. — *Liminatus Pharma, Inc. is a biotechnology company developing novel immune-modulating cancer therapies, including antibody-based immunotherapies and cellular therapies for solid tumors and hematologic malignancies; its lead candidate is IBA101, a humanized anti-CD47 monoclonal antibody.* Liminatus Pharma, Inc., a biotechnology company developing immune-modulating cancer therapies, executed a 1-for-50 reverse stock split of its common stock, effective August 20, 2026, to regain compliance with Nasdaq listing requirements. The company's Board approved the reverse split on August 3, 2026, following stockholder approval at the annual meeting held the same day. The reverse split reduces the outstanding share count from approximately 67,160,362 shares (as of July 2, 2026) to approximately 1,343,208 shares. On July 31, 2026, the Nasdaq Hearings Panel granted the company's request to transfer from The Nasdaq Global Market to The Nasdaq Capital Market and granted an exception to regain compliance with the minimum bid price rule by September 3, 2026. The company expects the reverse split will enable it to meet the $1.00 minimum closing bid price requirement.
  https://www.sec.gov/Archives/edgar/data/1971387/0001104659-26-098335.txt

## Citations
- 0001104659-26-098335 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926098335